Pharmacokinetics of Cefpirome Following Intravenous and Intramuscular Administration in Goats

被引：0

作者：

Barot, D. K. ^{[1
]}

Bhavsar, S. K. ^{[2
]}

Sadariya, K. A. ^{[1
]}

Soni, H. H. ^{[1
]}

Patel, R. J. ^{[1
]}

Patel, J. H. ^{[2
]}

Thaker, A. M. ^{[1
]}

机构：

[1] Anand Agr Univ, Coll Vet Sci & Anim Husb, Dept Pharmacol & Toxicol, Anand 388001, Gujarat, India

[2] Navsari Agr Univ, Coll Vet Sci & Anim Husb, Dept Pharmacol & Toxicol, Navsari 396450, India

来源：

ISRAEL JOURNAL OF VETERINARY MEDICINE | 2013年 / 68卷 / 02期

关键词：

cefpirome; pharmacokinetics; intravenous; intramuscular; goat; IN-VITRO ACTIVITY; BUFFALO CALVES; CEPHALOSPORIN; CEFEPIME; ANIMALS; PLASMA;

D O I：

暂无

中图分类号：

S85 [动物医学（兽医学）];

学科分类号：

0906 ;

摘要：

The pharmacokinetic profile of cefpirome following intravenous and intramuscular administration (10 mg/kg) was evaluated in goats. Cefpirome concentration in plasma samples was determined by reverse-phase High Performance Liquid Chromatography. Following intravenous administration of the cefpirome in goats, volume of distribution at steady-state (Vd(ss)), elimination half-life (t(1/2 beta)) and total body clearance (Cl-B) were 0.35 +/- 0.01 L/kg, 2.12 +/- 0.14 h and 2.13 +/- 0.05 ml/min/kg respectively. Following intramuscular administration of the drug, peak plasma concentration (C-max), elimination half-life (t(1/2 beta)) and bioavailability (F) were 10.97 +/- 0.34 mu g/mL, 2.09 +/- 0.08 h and 75 +/- 4 %, respectively. Plasma protein binding of cefpirome in goat was found to be 19.9 %. Pharmacokinetic - pharmacodynamic integration indicates cefpirome can be useful in goats at dose rate of 10 mg/kg and repeated at interval of 12 hours by the intramuscular route.

引用

页码：106 / 110

页数：5

共 20 条

[1]

Arayne MS, 2006, PAK J PHARM SCI, V19, P38

[2] INVITRO ACTIVITY OF HR-810, A NEW CEPHALOSPORIN [J].

BERTRAM, MA ;

BRUCKNER, DA ;

YOUNG, LS .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1984, 26 (02) :277-279

[3]

Bryskier A., Expert Opin Investig Drugs, DOI DOI 10.1517/13543784.3.2.145

[4] INTERRELATIONSHIP BETWEEN PHARMACOKINETICS AND PHARMACODYNAMICS IN DETERMINING DOSAGE REGIMENS FOR BROAD-SPECTRUM CEPHALOSPORINS [J].

CRAIG, WA .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1995, 22 (1-2) :89-96

[5] THE IMPORTANCE OF PHARMACOKINETIC-PHARMACODYNAMIC SURROGATE MARKERS TO OUTCOME - FOCUS ON ANTIBACTERIAL AGENTS [J].

HYATT, JM ;

MCKINNON, PS ;

ZIMMER, GS ;

SCHENTAG, JJ .

CLINICAL PHARMACOKINETICS, 1995, 28 (02) :143-160

[6] PHARMACOKINETICS OF CEFPIROME ADMINISTERED INTRAVENOUSLY OR INTRAMUSCULARLY TO RATS AND DOGS [J].

ISERT, D ;

KLESEL, N ;

LIMBERT, M ;

MARKUS, A ;

SEIBERT, G ;

SCHRINNER, E .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1992, 29 :31-37

[7] COMPARATIVE PHARMACOKINETICS OF SCE-2787 AND RELATED ANTIBIOTICS IN EXPERIMENTAL-ANIMALS [J].

KITA, Y ;

YAMAZAKI, T ;

IMADA, A .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (11) :2481-2486

[8] PHARMACOKINETIC PROPERTIES OF THE NEW CEPHALOSPORIN ANTIBIOTIC HR-8-10 IN ANIMALS [J].

KLESEL, N ;

SEEGER, K .

INFECTION, 1983, 11 (06) :318-321

[9] ANTIBACTERIAL ACTIVITIES INVITRO AND INVIVO AND PHARMACOKINETICS OF CEFQUINOME (HR-111V), A NEW BROAD-SPECTRUM CEPHALOSPORIN [J].

LIMBERT, M ;

ISERT, D ;

KLESEL, N ;

MARKUS, A ;

SEEGER, K ;

SEIBERT, G ;

SCHRINNER, E .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (01) :14-19

[10] In-vitro and in-vivo studies of cefpirom using bile salts as absorption enhancers [J].

Mrestani, Y ;

Bretschneider, B ;

Härtl, A ;

Neubert, RHH .

JOURNAL OF PHARMACY AND PHARMACOLOGY, 2003, 55 (12) :1601-1606

← 1 2 →